{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:37:28Z","timestamp":1786120648468,"version":"build-2736575974"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Tacrolimus is central to kidney transplant immunosuppression but causes toxicity. Optimal conversion regimens to sirolimus are unclear, and therapeutic drug monitoring is retrospective. We used pharmacokinetic (PK) modeling to identify conversion strategies to minimize under- or over-immunosuppression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Adult kidney transplant recipients converted from tacrolimus to sirolimus at a single center (March 2007\u2013January 2024) were reviewed. Demographics, conversion regimens, and therapeutic drug monitoring concentrations were collected. PK models were developed, conversion strategies were simulated using a combined tacrolimus\u2013sirolimus range of 8.5\u201311.6 ng\/mL, and relationships between drug exposure and laboratory outcomes were analyzed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Forty-five recipients underwent conversion. The most common approach halved tacrolimus for 5\u20137 days during sirolimus initiation. Tacrolimus and sirolimus clearance declined with age (\u22121.65% and \u22120.95% year\n                      <jats:sup>\u22121<\/jats:sup>\n                      , respectively). Sirolimus clearance fell with increasing hematocrit (\u22124.1% per percentage point). Tacrolimus dose predicted sirolimus needs (r = 0.62,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001). Higher combined exposure was associated with alanine transaminase elevation (r = 0.54,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.004). Mean glomerular filtration rate rose by 4.6 mL\u00b7min\n                      <jats:sup>\u22121<\/jats:sup>\n                      \u00b71.73 m\n                      <jats:sup>\u22122<\/jats:sup>\n                      after conversion (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001); white cell and platelet counts fell by 13.9% and 19.2%, respectively. Simulations favored Abbreviated Overlap with a sirolimus loading dose, achieving the greatest time within range (48.2% versus 40.2% for Standard Overlap). Immediate Switch without a loading dose resulted in 67.5% of the transition period below 8.5 ng\/mL.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>PK modeling supports risk-stratified protocol selection. Sirolimus dosing should be based on age, hematocrit, and tacrolimus requirements. Abbreviated Overlap with sirolimus loading is preferred for higher immunological-risk patients, and Standard Overlap for routine conversion. Laboratory monitoring preconversion and postconversion is necessary in clinical practice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/ftd.0000000000001515","type":"journal-article","created":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T00:00:21Z","timestamp":1786060821000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Optimizing Immunosuppressant Transition Strategies: Population Pharmacokinetic Analysis of Tacrolimus to Sirolimus Conversion in Renal Transplantation"],"prefix":"10.1097","author":[{"given":"Jessica","family":"Gadsby","sequence":"first","affiliation":[{"name":"Department of Pharmacy, University Hospitals of Leicester, NHS Trust, Leicester, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Page","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University Hospitals of Leicester, NHS Trust, Leicester, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dipesh","family":"Patel","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University Hospitals of Leicester, NHS Trust, Leicester, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damini","family":"Amin","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University Hospitals of Leicester, NHS Trust, Leicester, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Jesus-Silva","sequence":"additional","affiliation":[{"name":"Department of Nephrology, University Hospitals of Leicester, NHS Trust, Leicester, United Kingdom; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3171-691X","authenticated-orcid":false,"given":"Hussain","family":"Mulla","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University Hospitals of Leicester, NHS Trust, Leicester, United Kingdom;"},{"name":"College of Life Sciences, School of Healthcare, University of Leicester, Leicester, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,8,6]]},"reference":[{"key":"R1-20260806","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1111\/j.1600-6143.2009.02834.x","article-title":"KDIGO clinical practice guideline for the care of kidney transplant recipients","volume":"9","author":"Eckardt","year":"2009","journal-title":"Am J Transplant."},{"key":"R2-20260806","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/ajt.14557","article-title":"OPTN\/SRTR 2016 annual data report: kidney","volume":"18","author":"Hart","year":"2018","journal-title":"Am J Transpl."},{"key":"R3-20260806","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1016\/j.transproceed.2009.07.094","article-title":"Conversion to sirolimus for chronic allograft nephropathy and calcineurin-inhibitor toxicity and the adverse effects of sirolimus after conversion","volume":"41","author":"Sayin","year":"2009","journal-title":"Transpl Proc"},{"key":"R4-20260806","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/ajt.12969","article-title":"Sirolimus use and cancer incidence among US kidney transplant recipients","volume":"15","author":"Yanik","year":"2015","journal-title":"Am J Transpl."},{"key":"R5-20260806","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/TP.0b013e3181927a41","article-title":"Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial","volume":"87","author":"Schena","year":"2009","journal-title":"Transplantation"},{"key":"R7-20260806","doi-asserted-by":"crossref","first-page":"7808","DOI":"10.3390\/jcm14217808","article-title":"Tacrolimus-sirolimus combined exposure and acute rejection in kidney transplant recipients undergoing early conversion to sirolimus: a multicenter retrospective cohort threshold analysis","volume":"14","author":"Choi","year":"2025","journal-title":"J Clin Med"},{"key":"R8-20260806","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1097\/TP.0000000000000842","article-title":"A rationale for age-adapted immunosuppression in organ transplantation","volume":"99","author":"Krenzien","year":"2015","journal-title":"Transplantation"},{"key":"R9-20260806","doi-asserted-by":"crossref","first-page":"541","DOI":"10.2165\/00002512-200522070-00001","article-title":"Pharmacokinetic considerations relating to tacrolimus dosing in the elderly","volume":"22","author":"Staatz","year":"2005","journal-title":"Drugs Aging"},{"key":"R10-20260806","doi-asserted-by":"crossref","first-page":"323","DOI":"10.2478\/jomb-2018-0030","article-title":"Exploring sirolimus pharmacokinetic variability using routine clinical data from renal transplant patients: a population pharmacokinetic approach","volume":"38","author":"Golubovi\u0107","year":"2019","journal-title":"J Med Biochem"},{"key":"R11-20260806","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/164_2021_547","article-title":"Adverse effects of immunosuppression: nephrotoxicity, hypertension, and metabolic disease","volume":"272","author":"Hoosain","year":"2022","journal-title":"Handb Exp Pharmacol"},{"key":"R12-20260806","doi-asserted-by":"crossref","first-page":"6379","DOI":"10.2147\/DDDT.S503463","article-title":"Dosing-regimen recommendations for sirolimus in adult liver-transplant recipients: insights from a population pharmacokinetic model","volume":"18","author":"Mao","year":"2024","journal-title":"Drug Des Devel Ther"},{"key":"R13-20260806","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1186\/s40064-015-1425-5","article-title":"CYP3A5 and ABCB1 genotype influence tacrolimus and sirolimus pharmacokinetics in renal transplant recipients","volume":"4","author":"Li","year":"2015","journal-title":"SpringerPlus"},{"key":"R14-20260806","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/j.transproceed.2006.03.026","article-title":"Conversion from calcineurin inhibitors to sirolimus in patients with chronic renal allograft dysfunction","volume":"38","author":"Fischereder","year":"2006","journal-title":"Transpl Proc"},{"key":"R15-20260806","doi-asserted-by":"crossref","first-page":"167","DOI":"10.33549\/physiolres.933332","article-title":"Pathophysiological mechanisms of calcineurin-inhibitor\u2013induced nephrotoxicity and arterial hypertension","volume":"66","author":"Ho\u0161kov\u00e1","year":"2017","journal-title":"Physiol Res"},{"key":"R16-20260806","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1056\/NEJMoa067411","article-title":"Reduced exposure to calcineurin inhibitors in renal transplantation","volume":"357","author":"Ekberg","year":"2007","journal-title":"N Engl J Med"},{"key":"R17-20260806","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.trre.2011.10.003","article-title":"mTOR inhibitor-associated proteinuria in kidney transplant recipients","volume":"26","author":"Diekmann","year":"2012","journal-title":"Transpl Rev (Orlando)"},{"key":"R20-20260806","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1517\/14740338.2016.1132698","article-title":"Safety of mTOR inhibitors in adult solid-organ transplantation","volume":"15","author":"Ventura-Aguiar","year":"2016","journal-title":"Expert Opin Drug Saf"},{"key":"R21-20260806","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/j.1600-6143.2009.02940.x","article-title":"Clinical predictors of proteinuria after conversion to sirolimus in kidney-transplant recipients","volume":"10","author":"Padiyar","year":"2010","journal-title":"Am J Transpl."},{"key":"R22-20260806","doi-asserted-by":"crossref","first-page":"1126981","DOI":"10.3389\/fphar.2023.1126981","article-title":"Precision sirolimus dosing in children: potential for model-informed dosing and novel drug monitoring","volume":"14","author":"Shen","year":"2023","journal-title":"Front Pharmacol"},{"key":"R23-20260806","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/FTD.0000000000000640","article-title":"Therapeutic drug monitoring of tacrolimus\u2014personalized therapy: second consensus report","volume":"41","author":"Brunet","year":"2019","journal-title":"Ther Drug Monit"},{"key":"R24-20260806","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/j.kint.2023.06.021","article-title":"Personalized tacrolimus dosing using model-based Bayesian prediction: a prospective randomized clinical trial in kidney-transplant recipients","volume":"104","author":"Lloberas","year":"2023","journal-title":"Kidney Int"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/FTD.0000000000001515","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T00:00:24Z","timestamp":1786060824000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/FTD.0000000000001515"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,6]]},"references-count":21,"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001515","relation":{},"ISSN":["0163-4356","1536-3694"],"issn-type":[{"value":"0163-4356","type":"print"},{"value":"1536-3694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,6]]},"assertion":[{"value":"2026-01-20","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-26","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}